A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, M. Cornfeld, L. Cartee, A. R Abdul Razak, L. A. Stayner, Y. Wu, R. Greenwood, R. Singh, C. B. Lee, J. Bendell, H. A. Burris, G. Del Conte, C. Sessa, J. R. Infante

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences